The centrifugal blood pump market will continue to grow from 2025 to 2035 due to the increasingly emerging clinical needs and innovative integrative devices. One of the reasons for high emerging demand against circulatory support during highly complex cardiac surgery is the dramatic increase in vascular diseases worldwide.
This primarily involves one of the greatest applications of centrifugal pumps, which includes the management during open heart surgery, such as in heart transplants, coronary artery bypass grafting (CABG), and the procedure methods of left ventricular assist devices.
The market is projected to grow at a compound annual growth rate (CAGR) of approximately 3.6% from 2025 to 2035, increasing from USD 134.7 Million in 2025 to approximately USD 191.9 Million by 2035.
Metric Overview
| Metric | Value |
|---|---|
| Market Size (2025) | USD 134.7 Million |
| Market Value (2035) | USD 191.9 Million |
| CAGR (2025 to 2035) | 3.6% |
North America is expected to be the largest region in centrifugal blood pump with about 40% of the total market revenue share. The USA is likely to remain the leading area as health spending is very high and advanced infrastructural support coupled with players for key players in the market, as well as government initiatives for health care innovation. In addition, growing incidences of cardiovascular diseases will help raise market demand for this region.
Europe will have more than 30% of the share in the global market, making Germany, the UK, and France the major contributors to this market. The rising aged population along with the increasing incidences of heart diseases is causing the growth of centrifugal blood pump in this region. Additionally, in Europe, the advanced medical devices are widely and increasingly being incorporated into healthcare systems, promoting the acceleration of market growth.
Centrifugal blood pumps will witness the most growth in the Asia-Pacific region. Health infrastructure development, growing events of heart diseases, and investments in medical technology have received such interest in the factors contributing to the region's growth. China, India, and Japan are countries that have been upgrading their medical facilities and thus lead to the acceptance of centrifugal blood pumps into the region.
Device Durability and Hemocompatibility
Centrifugal blood pumps are important in cardiac and pulmonary mode of support; however, they undergo several technical challenges regarding durability and hemocompatibility. Haemolysis and thrombus formation from the long-time contact of blood remain on the table. The design needs constant refinements and testing.
High Cost and Complex Regulatory Approvals
The design and manufacture of these centrifugal blood pumps is an elaborate engineering exercise which must meet overwhelming regulations, contributing to their high cost. This includes the length and complexity of regulatory pathways that delay product launches and limit accessibility to markets, especially in the developing world.
Rising Demand for Cardiac Surgeries and ECMO
Increasing cardiac diseases and growing use of ECMO in ICUs is a demand driver. The centrifugal pump offers a safer and efficient means for temporary circulatory support with respect to high-risk surgeries and organ transplant procedures.
Technological Innovations and Miniaturization
Advances in miniaturized pump design, real-time monitoring systems integration, and biocompatibility improvements allow the next generation of centrifugal blood pumps. These innovations will allow enhanced design performance, improved patient safety, and further applications, including portable and home-based care solutions.
Indications of cardiovascular diseases may increase its common occurrence, as it will be increasingly used in extracorporeal life support systems. Centrifugal pumps have already been built into the standard protocols for cardiopulmonary bypass adopted by hospitals and intensive care units worldwide.
North America, being the strong clinical hub and early implant of new and/or innovative medical devices, is the largest market for centrifugal blood pumps. Similarly, Europe seems to be moving at a slow growth pace due to the rising adoption of different alternative therapeutic modalities for cardiovascular diseases as well as positive reimbursement schemes.
Market Shifts: A Comparative Analysis 2020 to 2024 vs. 2025 to 2035
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Adoption Environment | Limited to high-end surgical and critical care facilities |
| Design and Functionality | Focus on traditional designs with basic automation |
| Cost Considerations | High acquisition and maintenance costs limiting widespread use |
| Regulatory and Compliance | Slower global approvals and clinical trial demands |
| End-user Profile | Mostly academic hospitals and tertiary care centers |
| Innovation Drivers | Engineering-focused improvements |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Adoption Environment | Widespread adoption in mid-tier hospitals and mobile ECMO units |
| Design and Functionality | Smart pumps with adaptive flow control and integrated sensors |
| Cost Considerations | Development of cost-effective, reusable systems for broader application |
| Regulatory and Compliance | Harmonized global standards and expedited approval pathways |
| End-user Profile | Expansion to regional hospitals and specialized cardiac care centers |
| Innovation Drivers | Cross-sector collaborations integrating AI and remote monitoring tools |
Increased application of centrifugal blood pumps for heart failures, increased cardiovascular disease incidence and innovative technology related to new designs of pumps that are safer for cardiovascular surgeries, as well as temporary support in circulatory problems are driving the market in the USA for treatments for heart failure.
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 3.8% |
Increased heart failure cases and more sophisticated devices for cardiovascular therapeutics in hospitals are causing popularity for centrifugal blood pumps in the UK. Extra push to market comes from NHS-funded studies into making these pumps more effective and safer.
| Country | CAGR (2025 to 2035) |
|---|---|
| United Kingdom | 3.5% |
The focus has been firmly placed across the EU in enhancing the production of blood pumps that could lead into their next generation having superior biocompatibility and lifetime performance. Moreover, the research and development funding supplements the objectives directed towards further adoption in cardiology clinics and hospitals.
| Country | CAGR (2025 to 2035) |
|---|---|
| European Union | 3.7% |
The centrifugal blood pump market in Japan is enabled by improvements in mechanical circulatory support devices and well-established healthcare infrastructure. Because of a greater proportion of older people and hence higher spending on cardiovascular health, the market is expected to grow.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 3.4% |
This stability of centrifugal blood pump market growth in South Korea is attested by a high standard of health care, advancing technology, and government rules restricting the heart disease burden on patients. In addition, the buoyant infrastructure development in healthcare further supports the market.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 3.6% |
| By Motor Type | Market Share (2025) |
|---|---|
| Electronic | 63.4% |
Market share of electronic centrifugal heart pumps is anticipated to be at the 63.4% mark by 2025 due to the pumps' greater accuracy, energy efficiency, and advanced control algorithms in them. These pumps are most commonly involved in extracorporeal circulation processes during cardiopulmonary bypass (CPB) or ECMO in a critical care environment of cardiothoracic surgery.
Compared to mechanical pumps, electronic pumps allow improved speed control, use real-time feedback to reduce the blood-membrane interaction, and thus improve patient safety and clinical benefits. At the same time, the accelerating load of heart diseases globally and intelligent features incorporated into cardiac surgery machines-monitors and automated functions-in itself to demand advancement in electronic blood pumps.
These are gaining acceptance within high-acuity hospital areas as well as specialty surgical centers, thus further enhancing their domination in the market.
| By End User | Market Share (2025) |
|---|---|
| Hospitals | 71.2% |
Hospitals will account for the major share of the Centrifugal Blood Pump Market and will dominate with a 71.2% share by 2025. This is further attributed to the increase in the number of complex cardiovascular surgeries, along with the growing penetration of these systems in hospitals with advanced extracorporeal life support systems.
Centrifugal blood pumps will also undergo usage in open-heart surgeries and durable mechanical circulatory support, usually conducted in hospitals with cardiac ICUs. Hospitals have proper infrastructure and trained personnel to handle advanced systems of blood pumps postoperatively and monitor the patient's condition.
Major other factors contributing to increasing hospital demand include the growth in cardiac care centers, funding for healthcare infrastructures, and the increasingly susceptible aging population who have heart-related ailments. These institutions also serve as sites for training and innovation, with the use of new, more efficient electronic blood pumps still on the rise.
The global centrifugal blood pump market is witnessing steady growth due to the rising demand for improved cardiovascular treatment along with the rising prevalence of heart failure, which commands the use of extra corporeal circulatory support.
They form an important part of the cardiovascular surgery for cardiopulmonary bypass and support adequate hemodynamic stability either for use in ventricular assist devices (VAD) or during use. Moreover, advancement in technology such as magnetically levitated impellers and miniaturized portable designs is further improving the pump efficacy as well as safety of the patients and encouraging its utilization in hospitals and specialty clinics.
Market Share Analysis by Key Players
| Company Name | Estimated Market Share (%) |
|---|---|
| Abbott Laboratories | 25-30% |
| Medtronic PLC | 20-25% |
| LivaNova PLC | 15-20% |
| Terumo Corporation | 10-15% |
| Getinge AB | 8-12% |
| Others | 10-15% |
| Company Name | Key Offerings/Activities |
|---|---|
| Abbott Laboratories | Offers the CentriMag ® system, a magnetically levitated centrifugal pump widely used for short-term mechanical circulatory support. |
| Medtronic PLC | Provides the Bio- Medicus ™ pump for extracorporeal circulation, known for its smooth blood flow and durability during surgeries. |
| LivaNova PLC | Manufactures centrifugal blood pumps used in cardiac surgeries and heart-lung machines, emphasizing precision and biocompatibility. |
| Terumo Corporation | Develops the Capiox ® centrifugal blood pump series designed for reliable and gentle blood handling in open-heart surgeries. |
| Getinge AB | Offers innovative centrifugal pumps integrated with its heart-lung machine systems for effective perfusion management. |
Key Market Insights
Companies such as Abbott Laboratories (25-30%)
Abbott Company is a major player in the centrifugal blood pump market with the CentriMag® system that offers continued circulatory support to very ill patients. The design reduces trauma while ensuring maximum control of blood flow with a minimum amount of physical contact with the blood as the pump uses magnetically levitated technology.
Medtronic PLC (20-25%)
Medtronic has designed the Bio-Medicus™ pump. This product is usually implemented in cardiovascular surgeries and provides extracorporeal support for safety and efficacy. The reliability of this pump and appropriate use in combination with the ECMO and CPB systems has made this very popular on a global scale.
LivaNova Plc (15-20%)
LivaNova centrifugal pumps are coupled to their heart-lung machine systems and are by far the best popular engines in sustainable high-performance efficient cardiac procedures. It is more focused on improving surgical results as part of innovation in pump design.
Terumo Corporation (10-15%)
Capiox® is the hallmark name of Terumo with advanced fluid dynamics for perfect and optimal perfusion. These pumps are also used in minimally invasive and conventional cardiac surgery, which takes place all over the world.
Getinge AB (8-12%)
Getinge has perfusion systems in which centrifugal pumps are integrated, providing safe and controlled blood circulation during complex surgical procedures. Innovations and safety have made the company reach ground.
Other Key Players (10-15% Combined)
The overall market size for Centrifugal Blood Pump market was USD 134.7 Million in 2025.
The Centrifugal Blood Pump market is expected to reach USD 191.9 Million in 2035.
The demand for centrifugal blood pumps will be driven by rising cardiovascular surgeries, advancements in electronic motor technolog.
The top 5 countries which drives the development of Centrifugal Blood Pump market are USA, European Union, Japan, South Korea and UK.
Electronic Motor Pumps demand supplier to command significant share over the assessment period.
Explore Therapeutic Device Insights
Centrifugal Blood Pump Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
